Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Sildenafil citrate slightly reduces blood pressure in treated hypertensives patients.
However, it is unknown if the simultaneous use of sildenafil plus, at least, 3 classes of
antihypertensive agents in patients with resistant arterial hypertension may have a synergic
effect on the patients blood pressure. Moreover, sildenafil improves the endogen nitric oxide
effects. The nitric oxide is an important signaling molecule in the body that contributes to
vessel homeostasis by inhibiting vascular smooth muscle contraction and growth. Hypertension
often impaired NO pathways. Nitric oxide is produced by an enzyme, called nitric oxide
synthase (NOS3), that show some genetics variants, which means that this enzyme can be
different from person to person. Therefore, the objective of the present study is to examine
the influence of a genetic variant (known to affect NOS3 levels) in sildenafil acute effects
on hemodynamic and cardiovascular function. The investigators hypothesis is that individuals
with the genetic variant associated to higher levels of NOS3 will have more benefits from
sildenafil treatment.
Phase:
N/A
Details
Lead Sponsor:
University of Campinas, Brazil
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo